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ABSTRACT
TNF-like ligand 1A (TL1A) and its unique receptor death receptor 3 (DR3) acts 
as broad T-cell costimulator involved in regulatory mechanisms of adaptive immune 
response under physiological and pathological settings. Moreover, we have recently 
shown that TL1A negatively regulates B-cell proliferation. Despite increasing interest 
on the TL1A/DR3-axis functions, very little is known on its expression and role in 
leukemia. In this study, we investigated the expression and function of TL1A/DR3 
axis in chronic lymphocytic leukemia (CLL). DR3 was differentially expressed in 
activated CLL cells and predominantly detected in patients with early clinical stage 
disease. Soluble TL1A has been revealed in the sera of CLL patients where higher TL1A 
levels were associated with early stage disease. T cells, monocytes and leukemic B 
cells have been identified as major sources of TL1A in CLL. The relevance of these 
findings has been sustained by functional data showing that exogenous TL1A reduces 
CLL proliferation induced by stimulation of the B cell receptor. Overall, these data 
document the expression of the TL1A/DR3 axis in early-stage CLL. They also identify 
a novel function for TL1A as a negative regulator of leukemic cell proliferation that 
may influence the CLL physiopathology and clinical outcome at an early-stage disease.
INTRODUCTION
Death receptor 3 (DR3/TNFRSF25) is a member of the 
TNFR superfamily that contains a death domain (DD) as part 
of its intracellular domain [1–3]. DR3 expression is restricted 
to lymphocyte-enriched tissues, including peripheral blood 
leukocytes, thymus and spleen [4]. It is especially up-
regulated in activated T cells [4, 5]. Moreover, we have 
recently reported that it is also expressed on activated B cells 
[6]. The unique ligand for DR3 is TNF-like ligand 1A (TL1A/
TNFSF15), a member of the TNF superfamily [7–9]. TL1A 
is expressed in a variety of cell types, including activated 
endothelial cells, monocytes, macrophages, dendritic cells, 
and T cells [7, 10–13]. Ligation of DR3 with TL1A induces 
costimulation of T cells [5, 7, 11, 14] and the TL1A/DR3 axis 
is implicated in regulatory mechanisms of adaptive immune 
response under physiological and pathological settings [15]. 
In contrast with this activating function, we have recently 
showed that TL1A negatively regulates proliferation of B 
cells activated by BCR stimulation and IL-2 [6].
Chronic lymphocytic leukemia (CLL) patients 
exhibit a variable clinical course, with some patients 
having indolent disease and others experiencing a more 
accelerated course, treatment resistance and dismal 
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outcome [16, 17]. Although the reason for this outcome 
disparity is not fully understood, the variable clinical 
course of CLL reflects biological differences that are 
driven by intrinsic defects as well as external cues deriving 
from the microenvironment [18–20]. Both cell-intrinsic 
and microenvironment-mediated events converge on the 
activation of regulatory signaling pathways involved 
in processes promoting resistance to apoptosis and 
overturning the control of cell proliferation [18–20]. 
Indeed, although CLL has long been regarded as a disease 
of accumulation rather than proliferation, evidence 
from in vivo labeling experiments [21] and analysis of 
telomeres [22] has revealed that, in lymphoid tissues, 
CLL cells proliferate at a relatively high rate. Among 
the microenvironmental stimuli that may induce CLL 
proliferation, a fundamental role is played by the B-cell 
receptor (BCR) signaling, which also represents the most 
prominent pathogenic mechanism in CLL [23–25].
The proliferation rate is associated with disease 
activity and progression [21]. Therefore, molecular 
mechanisms altering the balance between cell proliferation 
and death in disfavor of cell proliferation may result in 
clearance of leukemic cells and influence the pathogenic 
process and clinical outcome. However, little is known 
to date on molecular mechanisms involved in negative 
regulation of CLL proliferation.
In this study, we report that CLL cells activated by 
BCR stimulation differentially express DR3 molecules, 
which is more frequently associated with early-stage 
disease. Consistently, soluble TL1A has been detected in 
sera of CLL patients with an early-stage disease. Moreover, 
we show that in CLL TL1A is produced by T cells, 
monocytes and leukemic B cells. Stimulation of DR3 with 
exogenous TL1A reduces CLL proliferation mediated by 
the BCR stimulation. Taken together, these results suggest 
that the molecular axis TL1A/DR3 is a feature of CLL 
early-stage disease and may play an important role in 
controlling the proliferation of leukemic cells.
RESULTS
DR3 is differentially expressed in activated CLL 
cells and relates to disease stage
DR3 expression was analyzed in CLL cells under 
basal (unstimulated) conditions and following BCR 
stimulation (anti-IgM-stimulated), at different time points. 
Under basal conditions, CLL cells expressed low levels 
of DR3 when they were either freshly isolated (median 
RMFI = 1.00, range = 1.00–1.99 RMFI, n = 35; data not 
shown) or cultured in the absence of exogenous stimuli 
(Figures 1A–1C). Following BCR stimulation, a fraction 
of leukemic cells expressed increased levels of surface 
DR3 (Figures 1A–1C) that was sustained for 72 hours in 
culture and maximal at 24 hours (Figure 1B). Therefore, 
all subsequent analyses were performed at the 24-hour 
time point. As shown in Figure 1C, stimulation of the BCR 
for 24 hours induced a statistically significant increase 
of DR3 expression in CLL cells (p < 0.001), with great 
variability amongst leukemic cell samples [variance (σ2) = 
6.33]. Comparison of anti-IgM-induced DR3 expression in 
leukemic and healthy-donor B cells (σ2 = 13.5) revealed no 
significant differences (Figure 1D). Flow cytometry data 
were then confirmed by Western blot analysis. DR3 exists 
as at least 11 isoforms generated by pre-mRNA alternative 
splicing. The major isoform has a molecular weight of 
47 kD [26]. Accordingly, several isoforms were identified in 
CLL lysates by antibody directed towards the intracellular 
domain of DR3 (Figure 1E). Those included the isoform at 
47 kD and an isoform at approximately 40 kD (Figure 1E). 
Consistent with flow cytometry data, BCR-stimulation 
increased or de novo induced all the two DR3 isoforms 
in some CLL cell samples (Figure 1E). To confirm the 
relevance of our findings, we analyzed DR3 expression in 
lymph-node specimens from CLL patients using a three-
color immunofluorescence approach. Figure 1F (panel A) 
shows that DR3 is expressed by many cells within the 
CLL lymph nodes. Panel B shows that many of the cells 
in this area express CD23. The merged figure in panel C 
(yellow) shows that DR3-positive cells also express CD23, 
suggesting that they may include CLL B cells.
To assess whether DR3 could be differentially 
expressed in prognostic classes of CLL patients, induced 
DR3 expression was evaluated in relation to clinical 
staging (according to Rai or Binet classification), standard 
molecular prognostic markers (IGHV, CD38 or ZAP-
70 status), or cytogenetics. Mann-Whytney test showed 
statistically significant concordance between higher 
induced DR3 expression and Rai 0 stage (Figure 2). In 
contrast, no significant association was detected between 
DR3 expression and Binet staging, the status of standard 
prognostic markers (IGHV, CD38, ZAP-70), or cytogenetics 
(Figure 2). Overall, these results show that DR3 expression 
identifies CLL patients at an early clinical stage disease and 
prompted us to detect the presence of TL1A in CLL.
TL1A is detected in CLL serum and is associated 
with early-stage disease and absence of CD38
Like other TNF members, TL1A contains a 
predicted transmembrane domain and a bioactive, 
proteolytically cleaved truncated form that can be 
released as a soluble factor [8]. The presence of DR3 
in CLL cells, led us to hypothesize that a soluble form 
of TL1A might be detected in the sera of CLL patients. 
Therefore, serum concentrations of TL1A were measured 
in patients for whom serum samples were available and 
in age-matched healthy donors. Serum levels of soluble 
TL1A were detected in a fraction of CLL patients (14/26; 
54%; σ2 = 9036) and healthy donors (6/11; 54%; σ2 = 
4721). No significant differences in TL1A concentrations 
were revealed between the two groups (Figure 3).
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To explore the pathophysiological impact of TL1A 
in CLL, serum TL1A concentrations were related to 
clinical staging (according to Rai or Binet classification), 
the prognostic marker status (IGHV, CD38 or ZAP-70), 
or cytogenetics (Figure 4). Remarkably, Mann-Whytney 
test showed statistically significant concordance 
between higher TL1A serum concentration and Rai 
0 stage or absence of CD38 expression. In contrast, 
differences of TL1A concentrations across CLL 
prognostic classes defined by Binet clinical staging, 
IGHV status, ZAP-70 expression, or cytogenetics were 
not statistically significant, although TL1A levels were 
tendentiously higher in patients at a Binet A stage, with 
mutated IGHV, ZAP-70 negative, or neutral/favorable 
cytogenetics. Overall, these data document the presence 
of TL1A in sera of CLL patients with an early clinical 
stage disease and prompted us to search for the cell 
source of TL1A in CLL.
Figure 1: DR3 surface expression in CLL cells. A. Representative example of DR3 flow cytometry analysis. Dashed line: isotypic 
control; regular line: anti-DR3 signal. B. Time course analysis of DR3 expression in unstimulated and anti-IgM-stimulated CLL cells (n = 8). 
C. Surface DR3 expression in unstimulated and anti-IgM-stimulated CLL cells (n = 36). Data are expressed as DR3-expression median 
fluorescence intensity (MFI) divided by isotype-matched control (relative median fluorescence intensity = RMFI). Comparison between 
unstimulated and anti-IgM-stimulated CLL cells was performed by the two-sample Wilcoxon signed rank sum test. D. Comparison of DR3 
expression between B cells from CLL samples (n = 36) and age-matched healthy donors (n = 10). Lines represent median values. Comparison 
was performed using the Mann-Whitney test. ns = not significant. E. Western blot analysis of cell lysates from purified CLL cells (n = 4), in 
unstimulated and anti-IgM stimulated conditions. Level of DR3 induction after anti-IgM stimulation is reported as fold change. F. Representative 
example of DR3 immunofluorescence analysis in CLL lymph-node tissue sections (n = 2). Panel A: pseudocolour image of DR3 (200×); Panel 
B: pseudocolour image of CD23 (200×); Panel C: merged pseudocolour image of CD23 (green), DR3 (red) and DNA (blu) (200×).
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Figure 2: Association of DR3 expression with prognostic parameters. DR3 expression was associated with clinical staging according 
to Rai or Binet classification, or with standard prognostic markers: IGHV status, CD38 and ZAP-70 expression, and cytogenetic risk categories. 
Lines represent median values. Comparison was performed using the Mann-Whitney test and Kruskal-Wallis test. ns = not significant.
Figure 3: Serum levels of TL1A in CLL patients and healthy donors. TL1A serum levels in 26 CLL samples and 11 age-
matched healthy donors were measured by ELISA assay. Lines represent median values. Comparison was performed using the Mann-
Whitney test. ns = not significant.
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TL1A is expressed by PBMC cell subsets from 
CLL and healthy donors
To identify the possible cell source of TL1A, first we 
analyzed specific TL1A mRNA expression in different cell 
subsets (CD3+, CD14+, CD19+) isolated by FACS from 
PBMCs of CLL patients and healthy donors. As shown 
in Figure 5A, TL1A gene was expressed in each analyzed 
subset showing a great variability among samples, with 
some samples exhibiting a clear positive TL1A expression 
and others showing TL1A relative expression values ≤ 1, 
which represents the mean TL1A mRNA across samples.
Next, we analyzed TL1A protein expression in the 
T-cell (CD3+), monocyte (CD68+), and B-cell (CD5+/CD19+ 
for CLL and CD19+ for healthy donors) subsets of CLL and 
healthy-donor PBMCs, using intracellular staining and flow 
cytometry in the presence of cytokine secretion inhibition 
(BFA). The CD68 pan-monocyte staining was used instead 
of the CD14 as PMA used in the next experimental step 
down-regulates CD14 expression. Consistent with data on 
TL1A-mRNA, within each analyzed cell subset from both 
CLL and healthy donors, the fraction of TL1A-expressing 
cells varied across samples, with some samples having a 
relevant percentage of positive cells and others showing 
no positive cells with respect to the control (Figure 5B). 
Interestingly, in TL1A-positive samples, TL1A appeared to 
be coordinately expressed, both in CLL and healthy donors 
(Figure 5B and data not shown).
Figure 4: Association of TL1A serum levels with prognostic parameters. TL1A serum level was associated with clinical staging 
according to Rai or Binet classification, or with standard prognostic markers: IGHV status, CD38 or ZAP-70 expression, cytogenetic risk 
categories. Lines represent median values. Comparison was performed using the Mann-Whitney test and Kruskal-Wallis test. ns = not significant.
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Figure 5: TL1A expression in PBMC cell subsets from CLL patients and healthy donors. A. Quantitative real-time PCR 
analysis of TL1A mRNA expression in FACS-isolated cell subsets (CD3+, CD14+, and CD19+) from CLL (n = 6) and healthy donors (n = 3). 
Gene expression was normalized vs β-actin expression and represented as relative expression of TL1A mRNA levels with respect to mean 
TL1A mRNA across samples (set as 1). Lines represent median values. B. TL1A protein expression analysis in gated-cell subsets (CD3+, 
CD68+, CD5+/CD19+, CD19+) of PBMCs from CLL patients (n = 3) and healthy donors (n = 3). PBMCs were unstimulated or stimulated 
with PMA/ionomycin (PMA) in presence of brefeldin A (BFA). Dot plots are representative examples of TL1A flow cytometry analysis 
in gated-cell subsets (CD3+, CD68+, CD5+/CD19+, CD19+) of PBMCs from CLL patient and healthy donor. Number in bold indicate the 
percentage of TL1A-positive cells.
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To determine whether TL1A expression was 
inducible, CLL and healthy-donor PMBCs were stimulated 
with PMA, in the presence of cytokine secretion inhibition 
(BFA). As shown in Figure 5B, PMA was able to increase 
or de novo induce TL1A protein in CD68+ cells of all the 
analyzed samples derived from CLL as well as healthy 
donors. Treatment with PMA induced increased TL1A 
levels or no change in the CD3+ and CD19+ subsets of 
healthy-donor PBMCs (Figure 5B). In contrast, PMA 
induced no change or even down-regulated TL1A 
expression within the CLL CD3+ and CD5+/CD19+ cell 
subsets in CLL samples (Figure 5B). The presence of DR3 
and its ligand TL1A in CLL led us to explore the possible 
function of TL1A in CLL.
Exogenous TL1A reduces CLL cell proliferation 
without affecting cell survival
Previous studies had shown that TL1A/DR3 
interactions in vitro enhance cell proliferation of activated 
T cells [11, 27–28]. On the contrary, we have recently 
documented an in vitro inhibitory function for TL1A on 
B-cell proliferation [6]. To investigate whether TL1A could 
modulate cell proliferation in CLL, purified B cells from 
CLL patients were incubated with exogenous, recombinant 
TL1A in the presence of anti-IgM stimulation, and cell 
proliferation was measured using MTT assay. Stimulation 
of leukemic cells with anti-IgM induced a variable 
proliferation response among the analyzed cells, the fold-
increase in cell number ranging from 1.2 to 4.5 (data not 
shown). Moreover, under these conditions, all the analyzed 
CLL cell samples but one expressed detectable amounts 
of surface DR3. To distinguish differential responses to 
TL1A, a greater than 20% decrease or increase response 
was selected as an arbitrary cut-off. As shown in Figure 6A, 
TL1A reduced proliferation in a fraction of CLL cell 
samples (TL1A-responder) whereas induced no change in 
the remaining samples (TL1A-non-responder). All TL1A-
responder samples expressed surface DR3 whereas the 
DR3-negative sample was in the non-responder group. No 
effect was observed when CLL cells were incubated with 
TL1A alone (data not shown). Remarkably, responsiveness 
to TL1A co-stimulation was more frequently detected in 
samples at an early stage disease at diagnosis [3 of the 4 
responder samples (75%) versus 4 of the 9 non-responder 
samples (44%) were Rai 0 at diagnosis], although the 
association between responsiveness to TL1A and Rai 0 
stage was not statistically significant (data not shown). No 
association was detected between TL1A responsiveness 
and Binet staging, the status of standard prognostic 
markers (IGHV, CD38 or ZAP-70), or cytogenetics (data 
not shown).
Depending on the cellular context in which DR3 is 
triggered, its activation can result in apoptosis induction 
[29]. This raised the possibility that reduced MTT values 
induced in CLL cells by TL1A were due to reduced cell 
survival. To test this, purified CLL-B cells were incubated 
with exogenous recombinant TL1A in the presence of 
anti-IgM, and cell survival was measured with Annexin 
V/PI staining and flow cytometry. As shown in Figure 6B 
and 6C, TL1A did not influence either the spontaneous 
apoptosis process or the protective effect exerted by anti-
IgM, thus demonstrating that reduced MTT values induced 
by TL1A in anti-IgM-activated CLL cells was due to 
decreased proliferation and not to reduced survival.
DISCUSSION
This study documents that the TL1A/DR3 molecular 
system is expressed in CLL and functions as a negative 
regulator of leukemic cell proliferation. Over the last 
decade, a number of evidence has traced a function of 
broad-acting T-cell stimulator for TL1A/DR3, particularly 
in inflammatory and autoimmune diseases [15, 30–31]. 
The key advance of this study is identifying for the first 
time a B-cell negative regulatory function for the TL1A/
DR3 system in a leukemic context. This study assesses 
the association between TL1A/DR3 expression and early 
stage disease and points out the importance of the TL1A/
DR3 axis in the physiopathology of CLL.
DR3 expression is restricted to lymphocyte-
enriched tissues and is especially upregulated in activated 
T cells [3]. B cells express a combination of DR3 mRNA 
isoforms [3] and we have recently described that B cells 
activated by the BCR stimulation express DR3 protein 
[6]. In this study, we show that leukemic B cells from 
CLL patients express surface DR3 in response to BCR 
stimulation. This result has been confirmed in CLL 
lymph nodes showing that DR3 may be expressed by 
leukemic cells, presumably activated in vivo by the 
antigen encounter. Indeed, in CLL antigenic stimulation 
is the most prominent pathogenic mechanism within the 
lymph-node microenvironment [23–25] and the signaling 
pathways triggered by the antigen encounter might also 
drive DR3 expression. In future studies, it would be of 
interest to identify the signaling key nodes involved in 
DR3 upregulation. Remarkably, DR3 is more frequently 
expressed in activated leukemic cells from CLL patients 
at an early clinical stage at diagnosis, suggesting a role 
for DR3 at this stage of disease. The relevance of DR3 
expression in CLL is confirmed by the presence, in the 
sera from CLL patients, of its unique ligand TL1A that, 
similarly to DR3 expression, is more frequently detected 
in CLL patients at an early-stage disease.
Importantly, exogenous recombinant TL1A reduces 
cell proliferation in a fraction of CLL cells activated by 
BCR stimulation. This result is consistent with our recent 
data showing that TL1A reduces proliferation of healthy 
B cells activated by BCR stimulation and IL-2 [6]. In 
contrast, in T cells the TL1A/DR3 axis has been described 
to act as a costimulator that promotes cell proliferation 
[11, 27–28]. Overall, these data confirm that either 
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stimulatory or inhibitory regulatory functions may be 
ascribed to the TL1A/DR3 axis, apparently depending on 
cellular and/or microenvironmental contexts.
The physiopathology of CLL is entwined with its 
microenvironment and over the last decade major efforts 
have been made to characterize driving molecular events 
that confer to CLL microenvironments peculiarity of 
permissive niches for cell proliferation and survival 
[19]. Within these microenvironments, a crucial role 
may be also played by inhibitory mechanisms of cell 
proliferation, which may alter the balance between cell 
death and proliferation favoring the clearance of leukemic 
cells. Accordingly, the differential expression of these 
mechanisms may have a direct impact on patients’ clinical 
outcome. Herein, we show that in some CLL patients and 
healthy donors, T cells, monocytes, and B cells are able 
to produce TL1A, apparently in a coordinate fashion. Our 
data are consistent with previous studies showing that 
monocytes and T cells are able to produce TL1A [11, 32] 
whereas they document for the first time the ability of 
leukemic and healthy B cells to express TL1A. Further 
studies will be required to identify the specific TL1A-
expressing cell subsets within the T-cell, monocyte, and 
B-cell populations.
Within the lymph nodes, interactions with 
T cells promote survival of CLL cells [33] whereas the 
monocyte-derived nurse-like cells support the survival 
and proliferation of CLL cells [34–36]. Besides this 
Figure 6: TL1A reduces CLL proliferation induced by stimulation of BCR with anti-IgM without affecting cell 
survival. A. CLL samples (n = 13) were stimulated with anti-IgM 5 μg/ml in the presence or absence of 100 ng/ml rTL1A for 96 h, 
and proliferation was analyzed using MTT assay. Proliferation in the presence of anti-IgM was referred as 100%. Data are represented 
as mean percentage ± SEM. Comparison between the TL1A-responder (n = 4) and TL1A-non-responder (n = 9) samples was performed 
using the Kruskal-Wallis test. B. Survival was analyzed by Annexin V/PI flow cytometry assay. The same CLL samples analyzed for 
proliferation (n = 13) were stimulated under the same conditions used for MTT assay, stained with Annexin V/PI and then analyzed by 
flow cytometry. Analyses were gated on CD5+/CD19+ cells. Comparison between treatments was performed using the Mann-Whitney test. 
ns = not significant. C. Figure shows a representative example of Annexin V/PI flow cytometry analysis.
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supportive role, our study suggests that T cells and 
monocytes may also play a regulatory role on CLL 
growth, presumably at an early-stage disease. Moreover, 
the finding that leukemic B cells may produce TL1A 
and express DR3 suggests the existence of an autocrine 
mechanism acting to regulate leukemic growth. Also, we 
show that similar regulatory mechanisms may be active 
in a healthy context.
Our study documents that TL1A may be 
upregulated following treatment with PMA in each 
analyzed cell subset from healthy donors and in the 
monocyte subset from CLL, consistent with previous 
data showing that TL1A mRNA is induced by PMA 
in HUVECs [7]. In contrast, in T cells and leukemic 
B cells from CLL patients, PMA induces no change 
or even TL1A downregulation. This behavior may be 
ascribed to functional defects and features of exhaustion 
documented in T cells from patients with CLL [37–39] 
whilst, in leukemic B cells, it may be due to functional 
alterations compatible with the anergic state described in 
the majority of CLL cells [40–43].
Herein, we document that expression as well as 
functional traits of TL1A/DR3 axis are predominantly 
observed in patients with an early disease specifically 
designated by the Rai 0 stage, irrespectively of the clinical 
stage as defined by the Binet classification system. Indeed, 
at variance with the Binet three-stage classification 
system, the Rai staging designates five clinical stages, thus 
allowing the identification of a low-risk, early-stage group 
of patients who are not captured by classification based on 
the Binet staging or the molecular prognostic parameters. 
Moreover, we have recently reported that the TL1A/
DR3 phenotypic and functional trait is also expressed 
in non-leukemic B cells, where it may have regulatory 
functions [6]. These findings lead us to hypothesize that 
in CLL the TL1A/DR3 functional axis may be preserved 
after the leukemic transformation, at least until the early 
stages of disease, where it may contribute to negatively 
regulate leukemic cell proliferation. In contrast, the 
TL1A/DR3 functional trait appears to be absent or 
impaired in advanced stages of CLL, thus representing an 
escape mechanism from the control of cell proliferation. 
Interestingly, our results are consistent with a study from 
Poggi et al. [44], which shows that lack of the inhibitory 
receptor LAIR-1 (leukocyte-associated Ig-like receptor 1) 
is associated with high-risk CLL. Moreover, it has been 
recently described that lack of LAIR-1 expression is able 
to predict CLL disease progression [45].
In conclusion, we propose a novel regulatory 
function for TL1A/DR3 that, differentially expressed 
in relation with clinical stage, may alter the balance 
between cell proliferation and death, influencing CLL 
physiopathology and clinical outcome. In addition to its 
pathogenic relevance, the presence of the TL1A/DR3 
system might represent a molecular marker for a finer 
classification of patients with early-stage disease.
MATERIALS AND METHODS
Cell and tissue samples
Peripheral blood mononuclear cells (PBMC) from 
36 CLL patients and 11 age-matched healthy donors were 
collected and cryopreserved at the Hematology Unit, 
Azienda Ospedaliera Universitaria Integrata (AOUI) in 
Verona (Italy); CLL tissue lymph-node specimens were 
collected at the Pathology Unit, AOUI. The local Ethics 
Committee (Comitato Etico per la Sperimentazione, 
AOUI) approved sample collection. In accordance with 
the Declaration of Helsinki, all patients provided written 
informed consent for the collection and use of their 
samples for research purposes. Patient inclusion criteria 
were the lack of prior treatment for at least 6 months prior 
to sample collection and availability of clinical annotation.
Diagnosis was based on 1996 National Cancer 
Institute-Working Group/IWCLL and 2008 Guidelines 
for Diagnosis and Treatment of CLL [46, 47]. CLL patient 
characteristics at diagnosis are summarized in Table 1. 
Patients were stratified into major cytogenetic categories, 
based on NCCN CLL Guidelines: favorable (13q as a sole 
aberration), neutral (normal karyotype, 12q trisomy), and 
unfavorable (11q and/or 17p deletion).
For DR3 surface expression, Western blot and 
proliferation experiments, B cells were isolated by 
negative selection using Human B-Cell Enrichment Kit, 
without CD43 depletion (Stem Cell Technologies Stem 
Cell Technologies, Vancouver, Canada).
Flow cytometry analysis
For analysis of DR3 surface expression, purified 
B cells from 36 patients and 10 healthy-donors were 
stimulated with sulfate latex beads (Interfacial Dynamics 
Corporation, Portland, OR, USA) [48] coated with anti-
IgM (cat#2022-01, SouthernBiotech, Birmingham, 
AL, USA). Purified B cells incubated with uncoated 
beads were used as control. Then, cells were harvested 
and stained with anti-DR3-PE (clone JD3, cat#307106, 
BioLegend, San Diego, CA, USA) or isotype-matched 
control antibody; anti-CD19-APC; anti-CD5-PE-Cy7 
and 7-amino-actinomycin (7-AAD) viable dye (all BD 
Biosciences, Franklin Lakes, NJ, USA).
For analysis of intracellular TL1A expression, 
PBMCs from 3 patients and 3 healthy-donors were 
cultured with 10 μg/ml brefeldin A (BFA) in presence 
or absence of 25 ng/ml phorbolmyristate (PMA), 
1 μg/ml ionomycin, for 6 hours. Cells were fixed and 
permeabilized with Fix&Perm® Kit (Nordic-MUbio, 
Susteren, Netherlands) and incubated with either anti-
TL1A mAb (clone L4G9, cat#ALX-804-832-C100, 
Enzo Life Sciences, Farmingdale, NY, USA) or 
isotype-matched control antibody, followed by staining 
with an anti-mouse-PE secondary antibody (Dako, 
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Glostrup, Denmark). Then, cells were incubated with 
anti-CD19-BV510, anti-CD5-V450, anti-CD-56-PE-
Cy7, anti-cPARP-AlexaFluor647 (all BD Biosciences), 
anti-CD68-AlexaFluor488, and anti-CD3-APC-Cy7 
(both BioLegend).
Samples were acquired on a FACSCanto II 
cytometer (Becton Dickinson, San Jose, CA, USA). DR3 
data were analyzed using FlowJo software (TreeStar, 
Ashland, OR, USA); TL1A data were analyzed using 
Kaluza software (Beckman Coulter, Miami, FL, USA). 
Table 1: Characteristics of CLL patients
n (%)
n 36
Age
Mean 64
Range 32–88
Gender
F 16 (44%)
M 20 (56%)
Rai stage
0 15 (42%)
I 11 (31%)
II 7 (19%)
III 0 (0%)
IV 3 (8%)
Binet stage
A 28 (78%)
B 5 (14%)
C 3 (8%)
IGHV status1
Mutated 17 (47%)
Unmutated 19 (53%)
CD382
Negative 19 (53%)
Positive 17 (47%)
ZAP-702
Negative 18 (50%)
Positive 18 (50%)
Cytogenetics3
Neutral 16 (44%)
Favorable 7 (19%)
Unfavorable 10 (28%)
n.a. 3 (8%)
1IGHV sequencing utilized a 2% cut-off to discriminate mutated from unmutated IGHV;
2Percent ZAP-70- and CD38-positive cells were determined by setting the threshold at 20% and 30%, respectively [49];
3Cytogenetic analysis was performed using fluorescence in situ hybridization (FISH) [50–51];
n.a. = not available.
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Median fluorescence intensity (MFI) was normalized with 
respect to MFI of control antibody. Fold change in DR3 
expression was calculated as the ratio between normalized 
signals (RMFI) of anti-IgM-stimulated and unstimulated 
cells.
Western blot analysis
Purified CLL-B cells from 4 patients, stimulated 
with anti-IgM-coated beads as for DR3 flow cytometry 
analysis, were lysed and 15 μg proteins were separated 
on a SDS-polyacrylamide gel and Western blotting was 
performed according to standard procedures, using anti-
DR3 antibody (cat# 3254, Cell Signaling Technology, 
Danvers, MA, USA) for detection. Signals were quantified 
with ImageJ software (http://rsb.info.nih.gov/ij/) and 
normalized calculating the ratio between DR3 and β-actin 
signals. DR3 fold change was calculated as the ratio 
between normalized signals of anti-IgM stimulated and 
unstimulated cells.
Lymph-node immunofluorescence
Immunofluorescence was performed on formalin-
fixed paraffin-embedded tissue lymph-node sections 
from 2 patients, as previously described [6]. Briefly, DR3 
expression was detected using anti-DR3-biotinylated 
mAb (clone JD3, cat#NB100–77847, Novus Biologicals, 
Cambridge, England). B cells were detected with anti-
CD23 and anti-mouse biotinylated secondary antibody 
(Leica Biosystems, Newcastle, England). Signals were 
revealed with Qdot Streptavidin Conjugates (QD565, 
QD655; Invitrogen, Eugene, OR, USA) and Qnuclear 
Deep Red Stain (Invitrogen). Slides were mounted with 
Qdot Qmount mounting media (Invitrogen). Images were 
acquired on a BX61 microscope (Olympus Optical, Tokyo, 
Japan) and elaborated with CellF software (Olympus Soft 
Imaging Solutions, Munster, Germany).
Enzyme-linked immunosorbent assay (ELISA)
Serum levels of TL1A were measured in 26 patients 
and 11 healthy donors using human TL1A ELISA kit 
(Alexis-Biochemical, San Diego, CA, USA), according 
to the manufacturer’s protocol. Absorbance was measured 
using VictorX4 plate reader (Perkin-Elmer, Monza, Italy). 
All samples were run in duplicate.
Cell sorting
PBMCs from 6 patients and 3 healthy donors 
were stained with anti-CD3-FITC, anti-CD19-PE (both 
BD Biosciences), anti-CD14-APC-Cy7 (BioLegend), 
and 7-AAD. Stained cells were analyzed and sorted 
on a FACSAria II instrument (Becton Dickinson), 
using FACSDiva software (Becton Dickinson). T cells, 
monocytes, and B cells were identified respectively on 
the basis of CD3, CD14, and CD19 expression. Purity of 
FACS-isolated cells was greater than 98%, as assessed by 
post-sorting analysis.
Quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from FACS-isolated 
CD3+, CD14+ and CD19+ cells from patients and healthy 
donors using TRIzol Reagent (Invitrogen), according to 
the manufacturer’s protocol. RNA was reverse transcribed 
and qRT-PCR carried out on ABI PRISM 7900HT SDS 
instrument (Applied Biosystems, Warrington, England). 
TNFSF15 (TL1A) was evaluated using Taqman assay 
Hs00353710_s1 (Applied Biosystems). TL1A expression 
was calculated by relative quantification, using ACTB 
(β-actin) expression as endogenous reference. Data 
were analyzed as indicated in User Bulletin #2 (Applied 
Biosystems). All samples were run in duplicate.
Proliferation assay
Cell proliferation was measured in 13 CLL samples 
using MTT (thiazolyl blue; Sigma-Aldrich, Milan, Italy), 
according to the manufacturer’s protocol. Briefly, purified 
CLL-B cells were stimulated with 5 μg/ml soluble 
anti-IgM in presence or absence of 100 ng/ml human 
recombinant TL1A (Peprotech, London, England) for 
96 hours, followed by 4 hour-incubation with MTT. 
Absorbance was measured using VictorX4 plate reader 
(Perkin-Elmer). All samples were run in duplicate.
Apoptosis assay
Apoptosis was detected in 13 CLL samples using 
Annexin V-FITC Apoptosis Detection kit (Bender 
MedSystem, Vienna, Austria), according to the 
manufacturer’s protocol. Briefly, purified CLL-B cells 
were stimulated with 5 μg/ml soluble anti-IgM in the 
presence or absence of 100 ng/ml human recombinant 
TL1A for 96 hours, followed by staining with Annexin 
V-FITC and PI and acquisition on a FACSCanto 
instrument (Becton Dickinson). Data were analyzed using 
Kaluza software (Beckman Coulter). All samples were run 
in duplicate.
Statistical analysis
Graphing and statistical analyses were performed 
using GraphPad Prism software (GraphPad Software Inc., 
La Jolla, CA, USA). Results obtained in independent 
experiments were expressed as mean ± SEM. As data 
were not normally distributed, the two-sample Wilcoxon 
signed-rank sum test was used to compare DR3 expression 
between unstimulated and anti-IgM-stimulated cells. 
Kruskal-Wallis test was used to compare proliferation data 
and DR3 and TL1A expression between the cytogenetic 
risk categories. Mann-Whitney test was used in all 
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other experiments. Differences between the data were 
considered significant for p-values < 0.05.
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